Dose: 0.143 mg/kg
Single Dose: 0.14 (0.143)
Frequency: 6 hourly
Route: PO
Instructions: Initially as Required

. It is of Synthetic origin and belongs to Opioid. It belongs to OPIATE agonist pharmacological group on the basis of mechanism of action and also classified in Analgesic pharmacological group.The Molecular Weight of Dipipanone (HCl) is 404.00. Its pKa is 8.5.

Dipipanone (HCl) is contraindicated in conditions like Diabetes mellitus,Ulcerative colitis,Respiratory depression,Obstetric pain,Airway obstruction,Biliary spasm.

The severe or irreversible adverse effects of Dipipanone (HCl), which give rise to further complications include Hypotension, Hypotension, Dependence, Agranulocytosis, Ischemic colitis, Generalized chorea, Hypersensitivity hepatitis.Dipipanone (HCl) produces potentially life-threatening effects which include Respiratory depression. which are responsible for the discontinuation of Dipipanone (HCl) therapy.The signs and symptoms that are produced after the acute overdosage of Dipipanone (HCl) include Hypotension, Respiratory depression, Deepening coma, Pinpoint pupils, Circulatory failure.The symptomatic adverse reactions produced by Dipipanone (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Vertigo, Drowsiness, Nausea, Vomiting, Restlessness, Constipation, Rashes, Confusion, Urticaria, Sedation, Hallucination, Facial flushing, Euphoria, Paranoid delusions, Mood changes, Confusion.

Dipipanone (HCl) is primarily indicated in conditions like Moderate to severe pain.

No data regarding the interactions of Dipipanone (HCl) was found.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store Below 25°C. Protect from Sunlight and Moisture.

Dipipanone should be used with extreme caution in patients with hyperthyroidism, adrenocortical insufficiency, prostatic hypertrophy, hypotension secondary to hypovolumic shock, diabetes mellitus and phaeochromocytoma. The dose should be reduced in patients with impaired renal or hepatic function.